Arrowhead Press Releases 
ARROWHEAD ANNOUNCES CLOSING OF $8.65 MILLION REGISTERED DIRECT OFFERING
Pasadena, CA – June 23, 2010 – Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has closed its previously announced registered direct offering of 6.6 million shares of common stock and warrants to purchase 3.3 million shares of common stock.
more...ARROWHEAD ANNOUNCES OFFERING OF COMMON STOCK AND WARRANTS
Pasadena, CA – June 17, 2010 – Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has priced and received firm commitments for a registered direct offering to raise $8.65 million through the sale of 6.6 million shares of its common stock, and warrants to purchase 3.3 million shares of common stock.
more...ARROWHEAD TO HOLD ANNUAL MEETING JUNE 16, 2010;
CEO PRESENTATION AVAILABLE VIA WEBCAST
PASADENA, Calif. –June 15, 2010– Arrowhead Research Corporation (NASDAQ: ARWR) today announced that its Annual Meeting of Stockholders will be held on Wednesday, June 16, 2010 at 10:00 am PT at the Sheraton Pasadena, 303 E. Cordova Street, Pasadena, CA.
more...ARROWHEAD TO REJOIN THE RUSSELL MICROCAP INDEX
PASADENA, Calif. –June 14, 2010– Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it will join the Russell Microcap® Index when Russell Investments reconstitutes its family of U.S. indexes, according to a preliminary list of additions posted June 11 on www.russell.com.
more...ARROWHEAD PORTFOLIO COMPANY, LEONARDO BIOSYSTEMS, RECEIVES $2.5 MILLION FUNDING FROM TEXAS EMERGING TECHNOLOGY FUND
PASADENA, Calif.—June 7, 2010—Arrowhead Research Corporation (Nasdaq: ARWR) announced today that its portfolio company, Leonardo Biosystems, has received a $2.5 million grant from the Texas Emerging Technology Fund, a state fund established to accelerate commercialization of new technologies.
more...ARROWHEAD RESEARCH ANNOUNCES CLINICAL DATA PRESENTATIONS AT THE 2010 ASCO ANNUAL MEETING ON JUNE 6, 2010
PASADENA, Calif. — June 1, 2010 — Arrowhead Research Corporation (NASDAQ: ARWR) today announced that interim data from the phase 1 clinical trial conducted by its majority-owned subsidiary, Calando Pharmaceuticals, will be presented at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting.
more...ARROWHEAD TO PRESENT AT NOBLE FINANCIAL SIXTH ANNUAL EQUITY CONFERENCE
PASADENA, Calif. –May 28, 2010– Arrowhead Research Corporation (NASDAQ: ARWR) today announced that Dr. Christopher Anzalone, Chief Executive Officer, will be presenting at the Noble Financial Sixth Annual Equity Conference at 10:30 a.m. EDT on June 8, 2010, at the Hard Rock Hotel in Hollywood, Florida.
more...Arrowhead Lead Scientific Advisor, Dr. Mauro Ferrari and Calando Pharmaceuticals’ siRNA drug delivery platform featured in Houston Chronicle
PASADENA, Calif. –May 27, 2010– Arrowhead Research Corporation (NASDAQ: ARWR) today announced that two articles of interest to Arrowhead stockholders appeared in the Houston Chronicle this week.
more...Unidym and Guardian Industries Form Partnership to Develop and Commercialize Carbon Coated Glass Products
Sunnyvale, CA - Unidym, a majority owned subsidiary of Arrowhead Research (NASDAQ: ARWR), announced today that it has entered an agreement with global glass manufacturer Guardian Industries to develop and commercialize carbon coated glass products for touch screen devices and other applications.
more...ARROWHEAD REPORTS FISCAL 2010 SECOND QUARTER FINANCIAL RESULTS
PASADENA, Calif. – Arrowhead Research Corporation (NASDAQ: ARWR)today announced financial results for its fiscal 2010 second quarter ended March 31, 2010.
more...Arrowhead Research to Report Second Quarter Fiscal 2010 Financial Results and Host Conference Call on Thursday, May 13, 2010
PASADENA, Calif. — May 7, 2010 — Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it will report its financial results for the fiscal 2010 second quarter ended March 31, 2010, on Thursday, May 13, 2010, at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
more...Arrowhead Announces The Appointment of Former FDA Commissioner And National Cancer Institute Director Dr. Andrew Von Eschenbach to Its Board of Advisors
PASADENA, Calif.—April 26, 2010—Arrowhead Research Corporation (Nasdaq: ARWR) announced today the appointment of Dr. Andrew von Eschenbach to its Scientific Advisory Board (SAB).
more...Arrowhead to Present at Upcoming Conferences
PASADENA, Calif.—April 20, 2010—Arrowhead Research Corporation (Nasdaq: ARWR) announced today that Dr. Christopher Anzalone, Chief Executive Officer, will be presenting at the following investor conferences
more...Arrowhead Regains Compliance with Rule 5550, NASDAQ $1.00 Minimum Bid Requirement
PASADENA, Calif. – April 15, 2010 – Arrowhead Research Corporation (NASDAQ: ARWR) today announced that, on April 14, 2010, it received a notification from the NASDAQ Stock Market indicating that the Company has regained compliance with NASDAQ Rule 5550(a)(2) in that the Company's closing bid price has been at $1.00 per share or greater for at least 10 consecutive business days.
more...CNT-Enabled Touch Sensitive MP-4 Players Based on Unidym's Printable CNT Films Displayed at China Electronics Fair
Sunnyvale, CA – Unidym, a majority owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), announced today that touch sensitive MP-4 players enabled by Unidym's transparent conductive films were displayed at the 75th China Electronics Fair.
more...Arrowhead Announces The Appointment of Nobel Laureate Dr. Leland Hartwell to Its Board of Advisors
PASADENA, Calif.—April 7, 2010—Arrowhead Research Corporation (Nasdaq: ARWR) announced today the appointment of Dr. Lee Hartwell to its Scientific Advisory Board.
more...Breaking the cell barrier
The publication of data from a Phase I trial of CALAA-01 provided the first proof of concept in man that systemically delivered short interfering RNA can be targeted to specific cells. Read (PDF)
White Paper
CALAA-01 Results Show Delivery Technology to Meet Critical Need in RNAi Therapeutics, Putting Arrowhead in Position to Monetize Asset. Read (PDF)
Arrowhead Research Subsidiary, Calando Pharmaceuticals, Provides First Proof of RNA Interference in Humans with Systemically Administered siRNA Therapeutic; Clinical Trial Results Published in Nature
PASADENA, Calif. – March 22, 2010 – Arrowhead Research Corporation (NASDAQ: ARWR) today announced that the clinical trial being conducted by majority-owned subsidiary, Calando Pharmaceuticals, Inc. has demonstrated systemic delivery of siRNA and the successful “silencing” of a widely recognized cancer gene via RNA interference (RNAi) in humans.
more...Caltech-led Team Provides Proof in Humans of RNA Interference Using Targeted Nanoparticles
PASADENA, Calif.—A California Institute of Technology (Caltech)-led team of researchers and clinicians has published the first proof that a targeted nanoparticle—used as an experimental therapeutic and injected directly into a patient’s bloodstream—can traffic into tumors, deliver double-stranded small interfering RNAs (siRNAs), and turn off an important cancer gene using a mechanism known as RNA interference (RNAi).
more...Arrowhead Receives Additional 180 Day Grace Period to Comply with the NASDAQ $1.00 Minimum Bid Requirement
PASADENA, Calif. – March 18, 2010 – Arrowhead Research Corporation (NASDAQ: ARWR) today announced that, on March 16, 2010, it received a notification from the NASDAQ Stock Market indicating that the Company will have an additional 180-day grace period, until September 13, 2010, to regain compliance with NASDAQ's $1.00 minimum bid requirement.
more...Arrowhead Reports Fiscal 2010 First Quarter Financial Results
PASADENA, Calif. – Arrowhead Research Corporation (NASDAQ: ARWR) today announced financial results for its fiscal 2010 first quarter ended December 31, 2009.
more...Arrowhead Research to Report First Quarter Fiscal 2010 Financial Results and Host Conference Call on Thursday,
February 11, 2010
PASADENA, Calif. - Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it will report its financial results for the fiscal 2010 first quarter ended December 31, 2009, on Thursday, February 11, 2009 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). To participate in the conference call, please dial 877-941-4774 or 480-629-9760. Investors may also access a live audio webcast of this conference call on the Company's website.
more...Unidym Adds Malcolm Gillis, Ph.D. to Board of Directors
Sunnyvale, CA - Unidym, Inc., a majority owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), today announced that Malcolm Gillis, Ph.D. has been appointed to its Board of Directors. Dr. Gillis served as the President of William Marsh Rice University from 1993 until 2004 and guided Rice to become a leader in the then emerging field of nanoscience. His distinguished academic career focused on economics and environmental public policy and included appointments at Duke University and Harvard University.
more...Arrowhead appoints Chief Financial Officer
Pasadena, CA - Arrowhead Research Corporation (NASDAQ: ARWR) today announced that Ken Myszkowski has been appointed as the Company's Chief Financial Officer. Mr. Myszkowski brings to Arrowhead a broad range of finance and accounting experience spanning two decades in both the public and private sectors, including, most recently, senior level positions at two publicly traded energy companies and, earlier in his career, in two early stage technology companies.
more...Arrowhead's Portfolio Company, Nanotope, Publishes Preclinical Data Demonstrating Cartilage Regeneration
PASADENA, Calif. - February 2, 2010 - Arrowhead Research Corporation (NASDAQ: ARWR) today announced publication in Proceedings of the National Academy of Sciences (PNAS) of a study using Nanotope's lead compound for cartilage regeneration. The study's authors, which include Nanotope co-founder Dr. Samuel Stupp, showed that Nanotope's bioactive nanofiber system promotes the growth of new cartilage in a rabbit model.
more...Unidym Announces Joint Venture to Market Printable CNT Electronics in Korea
Sunnyvale, CA – Unidym, Inc., a majority owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), today announced that it has signed a definitive agreement to create a joint venture partnership with Wisepower, a publicly traded Korean company (KOSDAQ: 040670), to market and co-develop Unidym’s proprietary film and electronic ink products into the Korean touch panel and display industries.
more...Unidym Completes Licensing Agreements to Expand Use of its Carbon Nanotube IP in Diverse Array of Applications
Sunnyvale, CA – Unidym, Inc., a majority owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), today announced that it has completed three licensing agreements for its nanotechnology intellectual property (IP) for use in applications such as aerospace and military products.
more...Arrowhead Research Corporation Subsidiary Tego Biosciences Sells IP Portfolio to Luna Innovations
PASADENA, California – December 28, 2009 – Arrowhead Research Corporation (NASDAQ: ARWR) today announced that its wholly owned subsidiary, Tego Biosciences, has completed a definitive asset purchase agreement for the sale of its non-cash intellectual property (IP) to Luna Innovations, Inc. (Nasdaq: LUNA), a developer and manufacturer of new-generation products that include pharmaceutical nanomedicines.
more...Arrowhead Reports Fiscal 2009 Fourth Quarter and Full-Year Financial Results
PASADENA, Calif. – December 22, 2009 – Arrowhead Research Corporation (NASDAQ: ARWR) today announced financial results for its fiscal 2009 fourth quarter and full-year ended September 30, 2009.
more...Arrowhead Research to Report Fiscal 2009 Fourth Quarter and Year-End Financial Results and Host Conference Call on Tuesday, December 22, 2009
PASADENA, Calif. — December 21, 2009 — Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it will report its financial results for the fiscal 2009 fourth quarter and year ended September 30, 2009, on Tuesday, December 22, 2009 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
more...Arrowhead Announces $3.2 Million Private Placement
PASADENA, California - December 17, 2009 - Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has raised approximately $3.2 million in gross proceeds from a private placement of approximately 5.0 million units.
more...Arrowhead Subsidiary, Unidym, Enters Into Joint Development Agreement With a Major Liquid Crystal Display (LCD) Manufacturer For Glass Based Liquid Crystal Displays
Sunnyvale, CA - Unidym, Inc, a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), announced today that it has entered into a joint development agreement with a major liquid crystal display (LCD) manufacturer.
more...Unidym and Nano-C Enter Exclusive License Agreement for Fullerene Derivatives Used in Solar Cells
Sunnyvale, CA - December 2, 2009 - Unidym, Inc., a majority owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), announced today that it has entered an exclusive license agreement with Nano-C for patents covering fullerene derivatives. The license provides Nano-C exclusive rights to U.S. Patent No. 5,739,376 and foreign counterparts in the field of photovoltaics.
more...Arrowhead Subsidiary Unidym, Inc. Enters into Third Year of Joint Development Program with Samsung Electronics for Flexible Displays
Pasadena, CA – November 11, 2009 – Arrowhead Research Corporation (NASDAQ: ARWR) announced today that its majority owned subsidiary, Unidym, Inc., has entered into a joint development agreement with Samsung Electronics Co., Ltd., a leading maker of liquid crystal display (LCD) panels, to extend their successful collaboration into a third year.
more...Arrowhead Subsidiary Calando Pharmaceuticals Expands Board of Directors
Arrowhead Research Corporation (NASDAQ: ARWR) today announced that its majority owned subsidiary, Calando Pharmaceuticals, Inc., has appointed Mostafa Analoui, Ph.D., and Bruce D. Given, MD, to its Board of Directors.
more...Arrowhead CEO Provides Update on Company Strategy and Operations
Arrowhead Research Corporation (NASDAQ: ARWR) President and Chief Executive Officer today issued the following letter to the Company's shareholders:
more...Arrowhead Receives NASDAQ Deficiency Notice Related to Minimum Bid Price
Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has received a deficiency letter from the NASDAQ Stock Market indicating that based on the Company’s closing bid price for the last 30 consecutive business days, the Company does not comply with the $1.00 minimum bid price as set forth in NASDAQ Marketplace Rule 5550(a)(2).
more...Arrowhead Regains Compliance with NASDAQ Listing Requirements
Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has received notification from the NASDAQ Stock Market that the Company has regained compliance with the minimum of $2.5 million in stockholders’ equity requirement for continued listing on the NASDAQ Capital Market, pursuant to NASDAQ Marketplace Rule 4310(c)(3).
more...Arrowhead Reports Third Quarter Fiscal 2009 Financial Results
Arrowhead Research Corporation (NASDAQ: ARWR) today announced financial results for its third fiscal quarter ended June 30 2009.
more...Arrowhead Announces Completion of $2.76 Million Private Placement
Arrowhead Research Corporation today announced that it has completed a second and final closing of its private offering with selected institutional and accredited investors bringing the proceeds of the offering to a total of $2.76 million.
more...Arrowhead Research to Report Fiscal Third Quarter 2009 Financial Results and Host Conference Call on Monday, August 10, 2009
PASADENA, Calif. — August 4, 2009 — Arrowhead Research Corporation (NASDAQ: ARWR today announced that it will report its financial results for the third quarter of fiscal 2009 ended June 30, 2009, on Monday, August 10, 2009 at 4:30 p.m. ET (1:30 p.m. PT). To participate in the conference call, please dial 888-846-5003 or 480-629-9856. Investors may also access a live audio webcast of this conference call on the Company's website at www.arrowheadresearch.com.
more...